Skip to main content
SpringerLink
Log in

Antiviral Therapy in AIDS

Clinical Pharmacological Properties and Therapeutic Experience to Date

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The rapid spread of human immunodeficiency virus (HIV) infections and the grim outcome of these infections have focused interest on the possibilities for medical intervention. The end- stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated in 1983. Already several antiviral drugs have been investigated. One initially promising drug, suramin, was found to have a net harmful effect but another, zidovudine (azidothymidine) has been shown to prolong life in AIDS patients. The properties of these and several other antiviral drugs such as antimoniotungstate (HPA- 23), foscarnet (phosphonoformate) ribavirin, dideoxynucleotides, and interferons, are reviewed. The role of immunomodulating modalities such as plasmapheresis, bone marrow transplantation, thymosin, interleukin- 2, inosine pranobex (isoprinosine), and cyclosporin are also discussed.

None of the currently available drugs holds promise as monotherapy. Through analysis of the experience with these drugs and the increasing knowledge of HIV pathogenesis, new drugs can be designed. It seems increasingly clear that drugs will eventually have to be used in combination in order to reduce toxicity, exploit therapeutic synergy, and reduce the risk of HIV resistance. The theoretical and experimental background for such combinations are currently being elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aboud M, Hassan Y. Accumulation and breakdown of RNA-deficient intracellular virus particles in interferon treated NIH-3T3 cells chronically producing Moloney murine leukemia virus. Journal of Virology 45: 489–495, 1983

    PubMed  CAS  Google Scholar 

  • Anand R, Moore J, Feorino P, Curran J, Srinivasan A. Rifabutine inhibits HTLV-III. Lancet 1: 97–98, 1986

    Article  PubMed  CAS  Google Scholar 

  • Arora SK. Correlation of structure and activity of ansamycins. Molecular structure of sodium rifamycin SV. Molecular Pharmacology 23: 133–140, 1983

    PubMed  CAS  Google Scholar 

  • Balzarini J, Mitsuya H, De Clercq E, Broder S. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/ lymphadenopathy associated virus (LAV). International Journal of Cancer 37: 451–457, 1986

    Article  CAS  Google Scholar 

  • Barns BM. Grim projections for AIDS epidemic. Science 232: 1589–1590, 1986

    Article  Google Scholar 

  • Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868–871, 1983

    Article  PubMed  CAS  Google Scholar 

  • Beldekas JC, Levy EM, Black P, von Krogh G, Sandström E. In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS. Lancet 2: 1128–1129, 1985

    Article  PubMed  CAS  Google Scholar 

  • Broder S. Inhibition of the in vitro infectivity and cytopathic effect of HTLV-III/LAV by purines and pyrimidines with the ribose moiety in a 2′,3′-dideoxy configuration. International AIDS Conference, Paris, Jun, 1986

  • Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, et al. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 2: 627–629, 1985

    Article  PubMed  CAS  Google Scholar 

  • Busch W, Brodt R, Ganser A, Helm EB, Stille W. Suramin treatment for AIDS. Lancet 2: 1247, 1985

    Article  PubMed  CAS  Google Scholar 

  • Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 32: 383–424, 1986

    Article  PubMed  CAS  Google Scholar 

  • Chandra P, Sarin PS. Selective inhibition of replication of the AIDS-associated virus HTLV-III/LAV by synthetic D-penicillamine. Drug Research 36: 184–186, 1986

    PubMed  CAS  Google Scholar 

  • Chang T-W, Heel RC. Ribavirin and inosiplex: a review of their present status in viral diseases. Drugs 22: 111–128, 1981

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD, Levine A, Mildvan A, Kaplan J, Rios A, et al. Suramin therapy in AIDS and related diseases: initial report of the US suramin working group. Abstract, p. 36, International AIDS Conference, Paris, Jun, 1986

  • Chou T-C, Talay P. Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs on enzyme inhibitors. Advances in Enzyme Regulation 22: 27–55, 1984

    Article  PubMed  CAS  Google Scholar 

  • Coffin J, Haase A, Levy JA, Montagnier L, Orozzlan S, et al. Human immunodeficiency viruses. Science 232: 697, 1986

    Article  PubMed  CAS  Google Scholar 

  • Collins JM, Klecker RW, Yarchoan R, Lane HC, Fauci AS, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. Journal of Clinical Pharmacology 26: 22–26, 1986

    PubMed  CAS  Google Scholar 

  • Cooney DA, Dalal M, Mitsuya H, McMahon JB, Nadkarni M, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine. Biochemical Pharmacology 35: 2065–2068, 1986

    Article  PubMed  CAS  Google Scholar 

  • Copelan EA, Rinehart JJ, Lewis M, Mathes L, Olsen R, et al. The mechanism of retrovirus suppression of human T-cell proliferation in vitro. Journal of Immunology 131: 2017–2020, 1983

    CAS  Google Scholar 

  • Crumpacker C, Bubley G, Lucey D, Hussey S, Conner J. Ribavirin enters cerebrospinal fluid. Lancet 2: 45–46, 1986

    Article  PubMed  CAS  Google Scholar 

  • Crumpacker C, Bubley C, Hussey S, Schnipper L, et al. Evaluation of oral ribavirin therapy on immunologic and viral parameters in AIDS and ARC. Paper presented at the International AIDS Conference, Paris, Jun, 1986

  • Dalgleish AG, Beverly PCL, Clapham PR, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763–767, 1984

    Article  PubMed  CAS  Google Scholar 

  • Danner SA, Schuurman H-J, Lange JMA, Meyling FHJG, Schellekens PTA, et al. Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome. Archives of Internal Medicine 146: 1133–1136, 1986

    Article  PubMed  CAS  Google Scholar 

  • Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. The trans-activator gene of the human T-cell lymphotropic virus type III is required for replication. Cell 44: 941–947, 1986

    Article  PubMed  CAS  Google Scholar 

  • De Clercq E. Suramin: a potent inhibitor of reverse transcriptases. Cancer Letters 8: 9–22, 1979

    Article  PubMed  Google Scholar 

  • De Clercq E. Specific targets for antiviral drugs. Biochemical Journal 205: 1–13, 1982

    PubMed  Google Scholar 

  • De Noronha F, Schäfer W, Essex M, Bolognesi DP. Influence of antisera to oncorna virus glycoprotein (gp 71) on the infection of cats with the feline leukemia virus. Virology 85: 617–621, 1978

    Article  PubMed  Google Scholar 

  • Donnelly RP, Tsang KY, Galbraight GMP, Wallace JI. Inhibition of interleukin-2-induced T-cell proliferation by sera from patients with the acquired immune deficiency syndrome. Journal of Clinical Immunology 6: 92–101, 1986

    Article  PubMed  CAS  Google Scholar 

  • Dormont D, Spire B, Barre-Sinoussi F, Montagnier L, Chermann JC. Inhibition of the RNA-dependent DNA polymerase of AIDS and AIDS retroviruses by HPA-23 (ammonium-21-tungsto-9-antimoniate). Annalès de Institute Pasteur/Virologie 136E: 75–83, 1985

    Article  CAS  Google Scholar 

  • Drew WL, Conant M, Illeman M, Miner RC, Glasky A. Efficacy of isoprinosine (INPX) against cytomegalovirus infection in homosexual men. Abstract, International AIDS Conference, Paris, Jun, 1986

  • Elie R, LaRoche AO, Arnouxe E, G~erin JM, Pierre G, et al. Thymic dysplasia in the acquired immunodeficiency syndrome. New England Journal of Medicine 308: 841–842, 1983

    Article  PubMed  CAS  Google Scholar 

  • Enjuanes L, Lee JC, Ihle JN. Antigenic specificities of the cellular immune response of C57B/6 mice to the Moloney leukemia/sarcoma virus complex. Journal of Immunology 122: 665–674, 1979

    CAS  Google Scholar 

  • Ernst M, Kern P, Flad H-D, Ulmer AJ. Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC). Journal of Clinical Immunology 6: 170–181, 1986

    Article  PubMed  CAS  Google Scholar 

  • Essex M, Hardy WD, Cotter SW, Jakowski RM, Sliski A. Naturally occurring persistent feline oncornavirus infections in the absence of disease. Infection and Immunity 11: 470–475, 1975

    PubMed  CAS  Google Scholar 

  • Eyster ME, Goedert JJ, Poon M-C, Preble OT. Acid labile interferon: a possible preclinical marker for acquired immunodeficiency in haemophilia. New England Journal of Medicine 309: 583–586, 1983

    Article  PubMed  CAS  Google Scholar 

  • Fisher J, Ricard L, Weiss R. The structure of the heteropolytungstate (NH4)Na [W21Sb9086]-14H2O: an inorganic cryptate. Journal of the American Chemistry Society 98: 3050–3052, 1976

    Article  Google Scholar 

  • Forwell M, Gray KG, MacSween RNM, Peel MG, Madhok R, et al. Immunosuppression following alloantigen exposure: a role for lymphocyte Fcγ-receptor blocking antibodies? Journal of Clinical and Laboratory Investigation 19: 53–57, 1986

    CAS  Google Scholar 

  • Furman PA, Fyfe JA, StClair MH, Weinhold K, Rideout JL, et al. Phosphorylation of 3′-azidothymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences, USA 83: 8333–8337, 1986

    Article  CAS  Google Scholar 

  • Goldstein AL, Low TLK, McAdoo M, McClure J, Thurman GB, et al. Thymosin alpha, isolation and sequence analysis of an immunologically active thymic peptide. Proceedings of the National Academy of Sciences, USA 74: 725–729, 1977

    Article  CAS  Google Scholar 

  • Goldstein AL, Naylor PH, Schulof RS, Simon GL, Sztein MB, et al. Thymosin in the staging and treatment of HTLV-III positive homosexuals and haemophiliacs with AIDS-related immune dysfunction. In Gupta (Ed.) AIDS-associated syndromes, pp. 129–140, Plenum Publishing Co, 1985

  • Goudsmit J, de Wolf F, Paul DA, Epstein LG, Lange JMA, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1: 177–180, 1986

    Article  Google Scholar 

  • Grody WW, Fligiel S, Naeim F. Thymus involution in the acquired immunodeficiency syndrome. Am. J. of Clin. Path. 84: 85–95, 1985

    CAS  Google Scholar 

  • Harper ME, Marselle LM. In situ hybridization — application to gene localization and RNA detection. Cancer Genetics and Cytogenetics 19: 73–80, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hartshorn KL, Sandström EG, Neumayer D, Parakis TJ, Chou TC, et al. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant α-A interferon. Antimicrob. Agents Chemoth. 30: 189–191, 1986a

    Article  CAS  Google Scholar 

  • Hartshorn KL, Vogt M, Sandstrom E, Crumpacker CS, et al. Effects of combination antiviral therapy on LAV-HTLV III replication in vitro. Abstract, International AIDS Conference, Paris, Jun, 1986

  • Helgstrand E, Eriksson B, Johansson NG, Lännero B, Larsson A, et al. Trisodium phosphonoformate: a new antiviral compound. Science 201: 819–821, 1978

    Article  PubMed  CAS  Google Scholar 

  • Hicks DR, Martin LS, Getchell JP, Heath JL, Francis DP, et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxygenol in vitro. Lancet 2: 1422–1423, 1985

    Article  PubMed  CAS  Google Scholar 

  • Hirsch MS, Kaplan JC. Prospects for therapy of HTLV-III infections. Annals of Internal Medicine 103: 750–755, 1985

    PubMed  CAS  Google Scholar 

  • Ho DD, Rota TR, Schooley RT, Kaplan JC, Allan JD, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurological syndromes related to the acquired immunodeficiency syndrome. N. Eng. J. Med. 313: 1493–1497, 1985a

    Article  CAS  Google Scholar 

  • Ho DD, Hartshorn KL, Rota TR, Andrews CK, Kaplan JC, et al. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet 1: 602–604, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Ho DD, Rota TR, Hirsch MS. Infection of monocytes/macrophages by human T-lymphotropic virus. Journal of Clinical Investigation 77: 712–715, 1986

    Article  Google Scholar 

  • Jasmin C, Chermann J-C, Herve G, Teze A, Souchay P, et al. In vivo inhibition of murine leukemia and sarcoma viruses by the heteropoly-anion 5-tungsto-2-antimonate. Journal of the National Cancer Institute 53: 469–474, 1974

    PubMed  CAS  Google Scholar 

  • Kiprov DD, Lippert R, Miller RG, Sandström E, Jones FR, et al. The use of plasmapheresis, lymphocytapheresis and Staph. protein A immunoadsorption as an immunomodulatory therapy in patients with AIDS and AIDS-related conditions. Journal of Clinical Apheresis 3: 133–139, 1986

    Article  PubMed  CAS  Google Scholar 

  • Klecker RW, Collins JM, Yarchoan R, Thomas R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clinical Pharmacology and Therapeutics 41: 407–412, 1987

    Article  PubMed  Google Scholar 

  • Kloster BE, Tomar EH, Spira TJ. Lymphocytotoxic antibodies in the acquired immune deficiency syndrome (AIDS). Clinical Immunology and Immunopathology 30: 330–335, 1984

    Article  PubMed  CAS  Google Scholar 

  • Kolitz JE, Weite K, Sykora K-W, Mertelsmann R. Interleukin 2: a review. Arzneimittel-Forschung/Drug Research 35: 1607–1615, 1985

    CAS  Google Scholar 

  • Kreiss JK, Koech D, Plummer FA, Holmes KK, Lightfoote M, et al. AIDS virus in Nairobi prostitutes. Spread of the epidemic to East Africa. New England Journal of Medicine 314: 414–418, 1986

    Article  PubMed  CAS  Google Scholar 

  • Krieg CJ, Ostertag W, Clauss U, Pragnell IB, Swetly P, et al. Increase in intracisternal A-type particles in Friend cells during inhibition of Friend virus (SFFV) release by interferon or azidothymidine. Experimental Cell Research 116: 21–29, 1978

    Article  PubMed  CAS  Google Scholar 

  • Krönke M, Schlick E, Waldmann TA, Vietta ES, Greene WC. Selective killing of human T-lymphotropic virus-I infected leukemic cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. Cancer Research 46: 3295–3298, 1986

    PubMed  Google Scholar 

  • Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, et al. Qualitative analysis of immune function in patients with acquired immunodeficiency syndrome: evidence for a selective defect in the soluble antigen recognition. N. Eng. J. Med. 313: 79–113, 1985

    Article  CAS  Google Scholar 

  • Lane HC, Masur H, Longo DL, Klein HG, Rook AH, et al. Partial reconstitution in a patient with the acquired immunodeficiency syndrome. New England Journal of Medicine 311: 1099–1103, 1984

    Article  PubMed  CAS  Google Scholar 

  • Larder BA, Darby G. Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir. Antimicrob. Agents Chemoth. 29: 894–898, 1986

    Article  CAS  Google Scholar 

  • Laurence J, Gottlieb MS, Kunkel HG. Soluble suppressor factor with acquired immune deficiency syndrome and its prodrome: elaboration in vitro by T lymphocytes-adherent cell interactions. Journal of Clinical Investigation 72: 2072–2081, 1983

    Article  PubMed  CAS  Google Scholar 

  • Levine AM, Gill PS, Cohen J, Hawkins JG, Formenti SC, et al. Suramin antiviral therapy in the acquired immunodeficiency syndrome: clinical, immunologic and virologic results. Annals of Internal Medicine 105: 32–37, 1986

    PubMed  CAS  Google Scholar 

  • Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimbukuro JM, et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225: 840–842, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lin TS, Prusoff WH. Synthesis and biological activity of several amino acid analogues of thymidine. Journal of Medicinal Chemistry 21: 109–112, 1978

    Article  PubMed  CAS  Google Scholar 

  • Lotze MT. Treatment of immunologic disorders in AIDS. In De Vita et al. (Eds) AIDS, JB Lippincott, Philadelphia, 1985

    Google Scholar 

  • Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA. In vivo administration of purified human interleukin 2. Half life and immunologic effects of the Jurkat cell-line derived interleukin 2. Journal of Immunology 134: 157–166, 1985

    CAS  Google Scholar 

  • Lowy DR. Transformation and oncogenesis: Retroviruses. In Fields (Ed.) Virology, Raven Press, New York, 1985

    Google Scholar 

  • Marwick C. Taskforce formed to coordinate study, testing of AIDS therapies. J. Am. Med. Assoc. 255: 1233–1242, 1986

    Article  CAS  Google Scholar 

  • Mathur-Waugh U, Mildvan D, Spigland I, Brun-Vezinet F, Barre-Sinoussi F, et al. Longitudinal assessment of persistent generalized lymphadenopathy (PGL) in homosexual men. Advances in Experimental Medicine and Biology 187: 93–96, 1985

    Article  Google Scholar 

  • Mayer KH, Stoddard AM, McCusker J, Ayotte D, Ferrani R, et al. Human T-lymphotropic virus type III in high-risk, antibody-negative homosexual men. Ann. Int. Med. 104: 194–196, 1986

    PubMed  CAS  Google Scholar 

  • McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T-lymphocytes. Lancet 2: 1367–1369, 1984

    Article  PubMed  CAS  Google Scholar 

  • McDougal JS, Cort SP, Kennedy MS, Cabridilla CD, Feorina PM, et al. Immunoassay for the detection and quantification of infectious human retrovirus, lympadenopathy-associated virus (LAV). Journal of Immunological Methods 76: 171–183, 1985

    Article  PubMed  CAS  Google Scholar 

  • Mills LB. Stimulation of T-cellular immunity by cutaneous application of dinitrochlorobenzene. Journal of the American Academy of Dermatology 14: 1089–1090, 1986

    Article  PubMed  CAS  Google Scholar 

  • Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleotides. Proceedings of the National Academy of Sciences, USA 83: 1911–1915, 1986

    Article  CAS  Google Scholar 

  • Mitsuya H, Jarrett RF, Matsukara M, di Marzo Veronese F, DeVico AL, et al. Long-term inhibition of HTLV-III/LAV (human immunodeficiency virus) DNA synthesis and RNA expression in T-cells protected by 2′,3′-dideoxynucleosides in vitro. Proceedings of the National Academy of Sciences, US 84: 2033–2037, 1987a

    Article  CAS  Google Scholar 

  • Mitsuya H, Matsukura M, Broder S. Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV. In Broder (Ed.) AIDS: Modern concepts and therapeutic challenges, pp. 303–333, Marcel Dekker, New York, 1987b

    Google Scholar 

  • Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, et al. Suramin protection of T-cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226: 172–174, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, et al. 3′-Azido-3′-deoxythymidine (BW A509U): a new antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus III/lymphadenopathy associated virus in vitro. Proceedings of the National Academy of Sciences, USA 82: 7096–7100, 1985

    Article  CAS  Google Scholar 

  • MMWR Reports on AIDS. Mortality and Morbidity Weekly Report, June 1981 through January 1985, Centers for Disease Control, Atlanta, 1985

  • Murray HW, Rubin BY, Masur H, Roberts RB. Impaired cell mediated response in the acquired immune deficiency syndrome: patients with opportunistic infections fail to secrete activating lymphokine and gamma interferon. New England Journal of Medicine 310: 883–889, 1984

    Article  PubMed  CAS  Google Scholar 

  • Ostertag W, Roesler G, Krieg CJ, Kind J, Cole T, et al. Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proceedings of the National Academy of Sciences, USA 71: 4980–4985, 1974

    Article  CAS  Google Scholar 

  • Palladino MA, Weite K. Interleukin regulation of the immune system (IRIS) in male homosexuals with acquired immune deficiency disease syndrome. Ann. NY Acad. Sci. 437: 535–539, 1984

    Article  PubMed  CAS  Google Scholar 

  • Pompidou A, Delsaux MC, Telvi L, Mace B, Coutance F, et al. Isoprinosine and imutiol: two potentially active compounds in patients with AIDS related complex. Cancer Res. 45 (Suppl.): 4671, 1985

    Google Scholar 

  • Popovic H, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continuous production of a cytopathic retro virus (HTLV-III) from patients with AIDS and pre-AIDS. Science 224: 479–500, 1984

    Article  Google Scholar 

  • Real FX, Oettgen HF, Krown SE. Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leucocyte A interferon. Journal of Clinical Oncology 4: 544–551, 1986

    PubMed  CAS  Google Scholar 

  • Redfield RR, Wright DC, Tramont EC. Special report the Walter Reed staging classification for HTLV-III/LAV infection. New England Journal of Medicine 314: 131–132, 1986

    Article  PubMed  CAS  Google Scholar 

  • Rouvroy D, Bogaerts J, Habyarimana J-B, Nzaramba D, van der Perre P. Short-term results with suramin for AIDS-related conditions. Lancet 1: 878–879, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rozenbaum W, Dormont D, Spire B, Vilmer E, Gentilini M, et al. Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. Lancet 1: 450–451, 1985

    Article  PubMed  CAS  Google Scholar 

  • Salahuddin SZ, Groopman JE, Markham PD, Saragadharan MG, Redfield RR, et al. HTLV-III in symptom-free seronegative persons. Lancet 2: 1418–1420, 1984

    Article  PubMed  CAS  Google Scholar 

  • Sandström EG, Andrews CA, Schooley RT, Byington R, Hirsch MS. Suppression of concavalin A-induced blastogenesis by HTLV-III-infected H9 cells. Clin. Immun. Immunopath. 40: 253–258, 1986

    Article  PubMed  Google Scholar 

  • Sandström EG, Kaplan JC, Byington R, Hirsch MS. Inhibition of human T-cell lymphotropic virus type III by phosphonoformate. Lancet 2: 1480–1482, 1985

    Article  Google Scholar 

  • Sarin PS, Gallo RC, Scheer DI, Crews F, Lippa AS. Effects of a novel compound (AL721) in HTLV-III infectivity in vitro. New England Journal of Medicine 313: 1289–1290, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Sarin PS, Sun DK, Thornton AH, Naylor PH, Goldstein AL. Neutralization of HTLV-III replication by antiserum to thymosin alpha 1. Science 232: 1135–1137, 1986

    Article  PubMed  CAS  Google Scholar 

  • Sarin PS, Taguchi Y, Sun D, Thornton A, Gallo RC, et al. Inhibition of HTLV-III replication by foscarnet. Biochemical Pharmacology 34: 4075–4079, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Serwadda D, Mugerwa RD, Sewankambo NK, Lwegeba AL, Carswell JW, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 2: 849–852, 1985

    Article  PubMed  CAS  Google Scholar 

  • Shannon WM. Selective inhibition of RNA viruses replication in vitro and evaluation of candidate antiviral agents in vivo. Annals of the New York Academy of Sciences 284: 472–507, 1977

    Article  PubMed  CAS  Google Scholar 

  • Shannon WM. Mechanisms of action and pharmacology: chemical agents. In Galasso et al. (Eds) Antiviral agents and viral infections of man, 2nd ed., pp. 55–121, Raven Press, New York, 1984

    Google Scholar 

  • Sidman CL, Marshall JD, Shultz LD, Gray PW, Johnson HM. Gamma interferon is one of several direct B cell-maturation lymphokines. Nature 309: 801–804, 1984

    Article  PubMed  CAS  Google Scholar 

  • Siegel JP, Lane HC, Stocks NI, Quinnan GV, Fauci AS. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. Journal of Biological Response Modifiers 4: 596–601, 1985

    PubMed  CAS  Google Scholar 

  • Singer A, Shearer GM. AIDS therapy by blocking CD4+ cells. Nature 320: 113, 1986

    Article  PubMed  CAS  Google Scholar 

  • Snyder Jr HW, Singhai MC, Zuckerman EE, Jones FR, Hardy JR WD. The feline oncornavirus-associated cell membrane antigen (FOCMA) is related to, but not distinguishable from, FeVL-C gp70. Virology 131: 315–327, 1983

    Article  PubMed  CAS  Google Scholar 

  • Snyder HW, Singhai MC, Hardy WD, Jones FR. Clearance of feline leukemia virus from persistently infected pet cats treated by extra-corporeal immunoadsorption is correlated with an enhanced antibody response to FeLV gp70. J. Immun. 32: 1538–1543, 1984

    Google Scholar 

  • Sodroski J, Goh WC, Rosen C, Dayton A, Terwilliger E, et al. A second post-transcriptional trans-activator gene required for HTLV-III replication. Nature 321: 412–417, 1986

    Article  PubMed  CAS  Google Scholar 

  • Sodroski J, Rosen C, Wong-Stahl F, Salahuddin SZ, Popovic M, et al. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science 227: 171–173, 1985

    Article  PubMed  CAS  Google Scholar 

  • Sundquist B, Larner E. Phosphonoformate inhibition of visna virus replication. Journal of Virology 30: 847–851, 1978

    Google Scholar 

  • Sundquist B, Öberg B. Phosphonoformate inhibits reverse transcriptase. Journal of General Virology 45: 273–281, 1979

    Article  PubMed  CAS  Google Scholar 

  • Tsang KY, Tangnavarad K, Solomon S, Bekesi JG. Modulation of T-and B-cell functions by isoprinosine in homosexual subjects with prodromata and in patients with acquired immune deficiency syndrome (AIDS). Journal of Clinical Immunology 4: 469–478, 1984

    Article  PubMed  CAS  Google Scholar 

  • Voeller B. Nonoxygenol-9 and HTLV-III. Lancet 1: 1153, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vogt M, Hirsch MS. Prevention and therapy of infections with human immunodeficiency virus. Rev. Infect. Dis. 8: 991–1000, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vrang L, Öberg B. PPi analogs as inhibitors of human T-lympotropic virus type III reverse transcriptase. Antimicrobial Agents and Chemotherapy 29: 867–872, 1986

    Article  PubMed  CAS  Google Scholar 

  • Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, et al. Expression of interleukin 2 receptors on activated human B cells. Journal of Experimental Medicine 160: 1450–1466, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wallace JI, Bekesi JG. A double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathy. Clinical Immunology and Immunopathology 39: 179–186, 1986

    Article  PubMed  CAS  Google Scholar 

  • Witkowski JT, Robins RK, Sidwell RW, Simon LN. Design, synthesis and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. Journal of Medicinal Chemistry 15: 1150, 1972

    Article  PubMed  CAS  Google Scholar 

  • Varchoan R, Broder S. Strategies for the pharmacological intervention against HTLV-III/LAV. In Broder (Ed.) AIDS: modern concepts and therapeutic challenges, pp. 335–360, Marcel Dekker, New York, 1987

    Google Scholar 

  • Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1: 575–580, 1986

    Article  PubMed  CAS  Google Scholar 

  • Zamecnik PC, Goodchild J, Taguchi Y, Sarin PS. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proceedings of the National Academy of Sciences, USA 83: 4143–4146, 1986

    Article  CAS  Google Scholar 

  • Zatz MM, Skotnick A, Bailey JM, Olivier JH, Goldstein AL. Mechanism of action of thymosin. Effects of aspirin and thymosin on the enhancement of IL-2 production. Immunopharmacology 9: 189–199, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Södersjukhuset, Karolinska Institute, 100 64, Stockholm, Sweden

    Eric G. Sandström & Joan C. Kaplan

  2. Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, Boston

    Eric G. Sandström & Joan C. Kaplan

Authors
  1. Eric G. Sandström
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan C. Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sandström, E.G., Kaplan, J.C. Antiviral Therapy in AIDS. Drugs 34, 372–390 (1987). https://doi.org/10.2165/00003495-198734030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198734030-00004

Keywords

Search

Navigation